1800795, rs1800872, rs3087243, rs755622 rs28362491, rs2240336, rs2476601) with the etanercept
efficacyCONNORS, J.M.,
SAVAGE, K.J,
JURCZAK, W,
LECH-MARANDA, E.,
SMOLEWSKI, P,
WALEWSKI, J,
STRAUS, D.J.,
YOUNES, A.,
ANSELL, S.M.,
KIM, W.S.,
GALLAMINI, A.,
ALEKSEEV, S.,
ILLÉS, A.,
ROSTA, A.,
PICARDI, M.,
ZINZANI, P.L.,
OKI, Y.,
FELDMAN, T.,
BARTLETT, N.L.,
CHEN, R.,
RAMCHANDREN, R.,
CUNNINGHAM, D.,
RADFORD, J.,
JOSEPHSON, N.C.,
SONG, E.,
SACHS, J.,
JOLIN, H.A.,
HUEBNER, D.,
LIU, R.,
LIPATOV, O.N. (2018) , 0.73 [95% CI, 0.45 to 1.18]; P=0.20). All secondary
efficacy end points trended in favor of A
permanent neonatal diabetes to address the key questions relating to long-term
efficacy and safety